Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer

References

• Madar S, Goldstein I, Rotter V. ‘Cancer associated fibroblasts’–more than meets the eye. Trends Mol Med 2013; 19:447-53; PMID:23769623; http://dx.doi.org/10.1016/j.molmed.2013.05.004
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15:178-96; PMID:24556840; http://dx.doi.org/10.1038/nrm3758
   PubMed Web of Science ®Google Scholar
• Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Trans Med 2014; 3:17; PMID:25050175; http://dx.doi.org/10.1186/2001-1326-3-17
   PubMedGoogle Scholar
• Bourdon MA, Wikstrand CJ, Furthmayr H, Matthews TJ, Bigner DD. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 1983; 43:2796-805; PMID:6342760
   PubMed Web of Science ®Google Scholar
• Chiquet M, Fambrough DM. Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol 1984; 98:1937-46; PMID:6202699; http://dx.doi.org/10.1083/jcb.98.6.1937
   PubMed Web of Science ®Google Scholar
• Erickson HP, Inglesias JL. A six-armed oligomer isolated from cell surface fibronectin preparations. Nature 1984; 311:267-9; PMID:6482952; http://dx.doi.org/10.1038/311267a0
   PubMed Web of Science ®Google Scholar
• Grumet M, Hoffman S, Crossin KL, Edelman GM. Cytotactin, an extracellular matrix protein of neural and non-neural tissues that mediates glia-neuron interaction. Proc Natl Acad Sci U S A 1985; 82:8075-9; PMID:2415980; http://dx.doi.org/10.1073/pnas.82.23.8075
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986; 47:131-9; PMID:2428505; http://dx.doi.org/10.1016/0092-8674(86)90374-0
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R, Tucker RP. Tenascins and the importance of adhesion modulation. Cold Spring Harbor Perspect Biol 2011; 3; PMID:21441591; http://dx.doi.org/10.1101/cshperspect.a004960
   PubMedGoogle Scholar
• Aukhil I, Slemp CC, Lightner VA, Nishimura K, Briscoe G, Erickson HP. Purification of hexabrachion (tenascin) from cell culture conditioned medium, and separation from a cell adhesion factor. Matrix 1990; 10:98-111; PMID:1695709; http://dx.doi.org/10.1016/S0934-8832(11)80176-9
   PubMedGoogle Scholar
• Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 2006; 244:143-63; PMID:16632194; http://dx.doi.org/10.1016/j.canlet.2006.02.017
   PubMed Web of Science ®Google Scholar
• Jones FS, Hoffman S, Cunningham BA, Edelman GM. A detailed structural model of cytotactin: protein homologies, alternative RNA splicing, and binding regions. Proc Natl Acad Sci U S A 1989; 86:1905-9; PMID:2467292; http://dx.doi.org/10.1073/pnas.86.6.1905
   PubMed Web of Science ®Google Scholar
• Taylor HC, Lightner VA, Beyer WF Jr, McCaslin D, Briscoe G, Erickson HP. Biochemical and structural studies of tenascin/hexabrachion proteins. J Cell Biochem 1989; 41:71-90; PMID:2482292; http://dx.doi.org/10.1002/jcb.240410204
   PubMedGoogle Scholar
• Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dynam: Off Pub Am Assoc Anatomists 2000; 218:235-59; PMID:10842355; http://dx.doi.org/10.1002/(SICI)1097-0177(200006)218:2%3c235::AID-DVDY2%3e3.0.CO;2-G
   PubMed Web of Science ®Google Scholar
• Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol: J Int Soc Matrix Biol 2000; 19:581-96; PMID:11102748; http://dx.doi.org/10.1016/S0945-053X(00)00106-2
   PubMed Web of Science ®Google Scholar
• Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene 2014.
   Web of Science ®Google Scholar
• Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10:741-54; PMID:19773805
   PubMed Web of Science ®Google Scholar
• Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer J Int Du Cancer 1996; 66:632-5; PMID:8647625; http://dx.doi.org/10.1002/(SICI)1097-0215(19960529)66:5%3c632::AID-IJC9%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhesion Commun 1994; 1:307-17; PMID:7521758; http://dx.doi.org/10.3109/15419069409097262
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995; 270:6243-5; PMID:7534307; http://dx.doi.org/10.1074/jbc.270.11.6243
   PubMed Web of Science ®Google Scholar
• Zhao Y, Young SL. TGF-beta regulates expression of tenascin alternative-splicing isoforms in fetal rat lung. Am J Physiol 1995; 268:L173-80; PMID:7532367
   PubMed Web of Science ®Google Scholar
• LaFleur DW, Fagin JA, Forrester JS, Rubin SA, Sharifi BG. Cloning and characterization of alternatively spliced isoforms of rat tenascin. Platelet-derived growth factor-BB markedly stimulates expression of spliced variants of tenascin mRNA in arterial smooth muscle cells. J Biol Chem 1994; 269:20757-63; PMID:7519614
   PubMed Web of Science ®Google Scholar
• Jensen MA, Wilkinson JE, Krainer AR. Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nat Struct Mol Biol 2014; 21:189-97; PMID:24440982; http://dx.doi.org/10.1038/nsmb.2756
   PubMed Web of Science ®Google Scholar
• Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res: Off J Am Assoc Cancer Res 1995; 1:1035-41; PMID:9816077
   PubMed Web of Science ®Google Scholar
• Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol 2004; 203:771-9; PMID:15221936; http://dx.doi.org/10.1002/path.1589
   PubMedGoogle Scholar
• Tuominen H, Pollanen R, Kallioinen M. Multicellular origin of tenascin in skin tumors–an in situ hybridization study. J Cutan Pathol 1997; 24:590-6; PMID:9449485; http://dx.doi.org/10.1111/j.1600-0560.1997.tb01089.x
   PubMedGoogle Scholar
• Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80; PMID:10629546; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4%3c475::AID-PATH462%3e3.0.CO;2-V
   PubMedGoogle Scholar
• Berndt A, Kollner R, Richter P, Franz M, Voigt A, Berndt A, Borsi L, Giavazzi R, Neri D, Kosmehl H. A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol 2010; 133:467-75; PMID:20237793; http://dx.doi.org/10.1007/s00418-010-0685-y
   PubMedGoogle Scholar
• Martina E, Degen M, Ruegg C, Merlo A, Lino MM, Chiquet-Ehrismann R, Brellier F. Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. FASEB J: Off Pub Fed Am Soc Exp Biol 2010; 24:778-87; PMID:19884327; http://dx.doi.org/10.1096/fj.09-140491
   PubMedGoogle Scholar
• Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97; PMID:12036947
   PubMed Web of Science ®Google Scholar
• Hakkinen L, Hildebrand HC, Berndt A, Kosmehl H, Larjava H. Immunolocalization of tenascin-C, alpha9 integrin subunit, and alphavbeta6 integrin during wound healing in human oral mucosa. J Histochem Cytochem: Off J Histochem Soc 2000; 48:985-98; PMID:10858276; http://dx.doi.org/10.1177/002215540004800712
   PubMedGoogle Scholar
• Imanaka-Yoshida K. Tenascin-C in cardiovascular tissue remodeling: from development to inflammation and repair. Circ J: Off J Jpn Circ Soc 2012; 76:2513-20; PMID:23064399; http://dx.doi.org/10.1253/circj.CJ-12-1033
   PubMedGoogle Scholar
• Wight TN, Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J Physiol Gastrointest Liver Physiol 2011; 301:G950-5; PMID:21512158; http://dx.doi.org/10.1152/ajpgi.00132.2011
   PubMed Web of Science ®Google Scholar
• Trebaul A, Chan EK, Midwood KS. Regulation of fibroblast migration by tenascin-C. Biochem Soc Trans 2007; 35:695-7; PMID:17635125; http://dx.doi.org/10.1042/BST0350695
   PubMed Web of Science ®Google Scholar
• To WS, Midwood KS. Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol: J Int Soc Matrix Biol 2010; 29:573-85; PMID:20708078; http://dx.doi.org/10.1016/j.matbio.2010.08.003
   PubMedGoogle Scholar
• Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H, Mikuz G. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004; 57:927-31; PMID:15333651; http://dx.doi.org/10.1136/jcp.2004.016576
   PubMedGoogle Scholar
• Chiquet-Ehrismann R, Orend G, Chiquet M, Tucker RP, Midwood KS. Tenascins in stem cell niches. Matrix Biol: J Int Soc Matrix Biol 2014; 37C:112-23; PMID:24472737; http://dx.doi.org/10.1016/j.matbio.2014.01.007
   PubMedGoogle Scholar
• Takahashi Y, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Ishibashi M, Takano Y, Akiyoshi S, Iwaya T, et al. Tumor-derived tenascin-C promotes the epithelial-mesenchymal transition in colorectal cancer cells. Anticancer Res 2013; 33:1927-34; PMID:23645740
   PubMed Web of Science ®Google Scholar
• Dandachi N, Hauser-Kronberger C, More E, Wiesener B, Hacker GW, Dietze O, Wirl G. Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol 2001; 193:181-9; PMID:11180164; http://dx.doi.org/10.1002/1096-9896(2000)9999:9999%3c::AID-PATH752%3e3.0.CO;2-V
   PubMedGoogle Scholar
• Beiter K, Hiendlmeyer E, Brabletz T, Hlubek F, Haynl A, Knoll C,, Kirchner T, Jung A. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene 2005; 24:8200-4; PMID:16091738
   PubMed Web of Science ®Google Scholar
• Katoh D, Nagaharu K, Shimojo N, Hanamura N, Yamashita M, Kozuka Y, Imanaka-Yoshida K, Yoshida T. Binding of alphavbeta1 and alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis 2013; 2:e65; PMID:23958855; http://dx.doi.org/10.1038/oncsis.2013.27
   PubMed Web of Science ®Google Scholar
• Ramos DM, Dang D, Sadler S. The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res 2009; 29:125-30; PMID:19331141
   PubMed Web of Science ®Google Scholar
• Brunner A, Tzankov A. The role of structural extracellular matrix proteins in urothelial bladder cancer (review). Biomarker Insights 2007; 2:418-27; PMID:19662222
   PubMedGoogle Scholar
• Tiitta O, Wahlstrom T, Virtanen I, Gould VE. Tenascin in inflammatory conditions and neoplasms of the urinary bladder. Virchows Archiv B, Cell Pathol Including Mol Pathol 1993; 63:283-7; PMID:7685960; http://dx.doi.org/10.1007/BF02899274
   PubMedGoogle Scholar
• Deen S, Ball RY. Basement membrane and extracellular interstitial matrix components in bladder neoplasia–evidence of angiogenesis. Histopathology 1994; 25:475-81; PMID:7532615; http://dx.doi.org/10.1111/j.1365-2559.1994.tb00010.x
   PubMedGoogle Scholar
• Wilson CB, Leopard J, Cheresh DA, Nakamura RM. Extracellular matrix and integrin composition of the normal bladder wall. World J Urol 1996; 14 Suppl 1:S30-7; PMID:8738408; http://dx.doi.org/10.1007/BF00182062
   PubMedGoogle Scholar
• Champelovier P, El Atifi M, Mantel F, Rostaing B, Simon A, Berger F, Seigneurin D. In vitro tumoral progression of human bladder carcinoma: role for TGFbeta. Eur Urol 2005; 48:846-51; PMID:16046050; http://dx.doi.org/10.1016/j.eururo.2005.06.005
   PubMedGoogle Scholar
• Booth C, Harnden P, Selby PJ, Southgate J. Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol 2002; 198:359-68; PMID:12375269; http://dx.doi.org/10.1002/path.1214
   PubMedGoogle Scholar
• Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005; 95:655-9; PMID:15705098; http://dx.doi.org/10.1111/j.1464-410X.2005.05357.x
   PubMedGoogle Scholar
• Gazzaniga P, Nofroni I, Gandini O, Silvestri I, Frati L, Agliano AM, Gradilone A. Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncol Rep 2005; 14:1199-202; PMID:16211285
   PubMed Web of Science ®Google Scholar
• Berndt A, Anger K, Richter P, Borsi L, Brack S, Silacci M, Franz M, Wunderlich H, Gajda M, Zardi L, et al. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol 2006; 132:537-46; PMID:16788848; http://dx.doi.org/10.1007/s00432-006-0106-8
   PubMedGoogle Scholar
• Matsuda A, Tagawa Y, Yamamoto K, Matsuda H, Kusakabe M. Identification and immunohistochemical localization of annexin II in rat cornea. Curr Eye Res 1999; 19:368-75; PMID:10520233; http://dx.doi.org/10.1076/ceyr.19.4.368.5306
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao Z, Ma Y, Wang H, Ma J, He X, Zhang D. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma. Urologic Oncol 2014; 32:798-805; PMID:24968947; http://dx.doi.org/10.1016/j.urolonc.2014.02.009
   PubMedGoogle Scholar
• Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7:883-92; PMID:8816995; http://dx.doi.org/10.1091/mbc.7.6.883
   PubMedGoogle Scholar
• Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS, Shaw JA, Walker RA, Pringle JH, Jones JL. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res: BCR 2009; 11:R24; PMID:19405959; http://dx.doi.org/10.1186/bcr2251
   PubMed Web of Science ®Google Scholar
• Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995; 270:8650-4; PMID:7536739; http://dx.doi.org/10.1074/jbc.270.15.8650
   PubMed Web of Science ®Google Scholar
• Richter P, Tost M, Franz M, Altendorf-Hofmann A, Junker K, Borsi L, Neri D, Kosmehl H, Wunderlich H, Berndt A. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009; 135:1351-8; PMID:19326143; http://dx.doi.org/10.1007/s00432-009-0576-6
   PubMedGoogle Scholar
• Gecks T, Junker K, Franz M, Richter P, Walther M, Voigt A, Neri D, Kosmehl H, Wunderlich H, Kiehntopf M, et al. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder? Clinica Chimica Acta; Int J Clin Chem 2011; 412:1931-6; PMID:21763295; http://dx.doi.org/10.1016/j.cca.2011.06.038
   PubMed Web of Science ®Google Scholar
• Harada T, Shinohara M, Nakamura S, Oka M. An immunohistochemical study of the extracellular matrix in oral squamous cell carcinoma and its association with invasive and metastatic potential. Virchows Archiv: Int J Pathol 1994; 424:257-66; PMID:7514477; http://dx.doi.org/10.1007/BF00194609
   PubMedGoogle Scholar
• Shrestha P, Sakamoto F, Takagi H, Yamada T, Mori M. Enhanced tenascin immunoreactivity in leukoplakia and squamous cell carcinoma of the oral cavity: an immunohistochemical study. Eur J Cancer Part B, Oral Oncol 1994; 30B:132-7; PMID:7518275; http://dx.doi.org/10.1016/0964-1955(94)90065-5
   PubMedGoogle Scholar
• Tiitta O, Happonen RP, Virtanen I, Luomanen M. Distribution of tenascin in oral premalignant lesions and squamous cell carcinoma. J Oral Pathol Med: Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol 1994; 23:446-50; PMID:7532219; http://dx.doi.org/10.1111/j.1600-0714.1994.tb00442.x
   PubMedGoogle Scholar
• Atula T, Hedstrom J, Finne P, Leivo I, Markkanen-Leppanen M, Haglund C. Tenascin-C expression and its prognostic significance in oral and pharyngeal squamous cell carcinoma. Anticancer Res 2003; 23:3051-6; PMID:12926160
   PubMed Web of Science ®Google Scholar
• Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer J Int Du Cancer 2003; 106:683-9; PMID:12866027; http://dx.doi.org/10.1002/ijc.11283
   PubMed Web of Science ®Google Scholar
• Wang Z, Han B, Zhang Z, Pan J, Xia H. Expression of angiopoietin-like 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma. Biomar: Biochem Indic Expo, Resp Susceptibility Chem 2010; 15:39-46; PMID:19775228; http://dx.doi.org/10.3109/13547500903261362
   PubMedGoogle Scholar
• Choi P, Jordan CD, Mendez E, Houck J, Yueh B, Farwell DG, Futran N, Chen C. Examination of oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol–Head Neck Surg 2008; 134:539-46; PMID:18490578; http://dx.doi.org/10.1001/archotol.134.5.539
   PubMed Web of Science ®Google Scholar
• Mori M, Muramatsu Y, Yamada K, Shrestha P, Takai Y. Intracellular localization of tenascin in squamous cell carcinoma of oral cavity: an immunohistochemical study. Anticancer Res 1996; 16:3075-9; PMID:8920770
   PubMed Web of Science ®Google Scholar
• Fialka F, Gruber RM, Hitt R, Opitz L, Brunner E, Schliephake H, Kramer FJ. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma–a pilot study. Oral Oncol 2008; 44:941-8; PMID:18234543; http://dx.doi.org/10.1016/j.oraloncology.2007.10.011
   PubMed Web of Science ®Google Scholar
• Ramos DM, Chen BL, Boylen K, Stern M, Kramer RH, Sheppard D, Nishimura SL, Greenspan D, Zardi L, Pytela R. Stromal fibroblasts influence oral squamous-cell carcinoma cell interactions with tenascin-C. Int J Cancer J Int Du Cancer 1997; 72:369-76; PMID:9219848; http://dx.doi.org/10.1002/(SICI)1097-0215(19970717)72:2%3c369::AID-IJC28%3e3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Ramos DM, Chen B, Regezi J, Zardi L, Pytela R. Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer JInt Du Cancer 1998; 75:680-7; PMID:9495234; http://dx.doi.org/10.1002/(SICI)1097-0215(19980302)75:5%3c680::AID-IJC4%3e3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Berndt A, Borsi L, Hyckel P, Kosmehl H. Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol 2001; 127:286-92; PMID:11355143; http://dx.doi.org/10.1007/s004320000205
   PubMedGoogle Scholar
• Franz M, Hansen T, Richter P, Borsi L, Bohmer FD, Hyckel P, Schleier P, Katenkamp D, Zardi L, Kosmehl H, et al. Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front. Histochem Cell Biol 2006; 126:125-31; PMID:16344911; http://dx.doi.org/10.1007/s00418-005-0126-5
   PubMedGoogle Scholar
• Franz M, Hansen T, Borsi L, Geier C, Hyckel P, Schleier P, Richter P, Altendorf-Hofmann A, Kosmehl H, Berndt A. A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy. J Oral Pathol Med: Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol 2007; 36:6-11; PMID:17181735; http://dx.doi.org/10.1111/j.1600-0714.2006.00492.x
   PubMedGoogle Scholar
• Thomas GJ, Nystrom ML, Marshall JF. Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med: Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol 2006; 35:1-10; PMID:16393247; http://dx.doi.org/10.1111/j.1600-0714.2005.00374.x
   PubMed Web of Science ®Google Scholar
• Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002; 38:332-6; PMID:12076695; http://dx.doi.org/10.1016/S1368-8375(01)00062-8
   PubMed Web of Science ®Google Scholar
• Dang D, Yang Y, Li X, Atakilit A, Regezi J, Eisele D, Ellis D, Ramos DM. Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 2004; 316:937-42; PMID:15033492; http://dx.doi.org/10.1016/j.bbrc.2004.02.143
   PubMed Web of Science ®Google Scholar
• Ylipalosaari M, Thomas GJ, Nystrom M, Salhimi S, Marshall JF, Huotari V, Tervahartiala T, Sorsa T, Salo T. Alpha v beta 6 integrin down-regulates the MMP-13 expression in oral squamous cell carcinoma cells. Exp Cell Res 2005; 309:273-83; PMID:16024014; http://dx.doi.org/10.1016/j.yexcr.2005.06.008
   PubMedGoogle Scholar
• Richter P, Umbreit C, Franz M, Berndt A, Grimm S, Uecker A, Böhmer FD, Kosmehl H, Berndt A. EGF/TGFbeta1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J Oral Pathol Med: Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol 2011; 40:46-54; PMID:20819124; http://dx.doi.org/10.1111/j.1600-0714.2010.00936.x
   PubMedGoogle Scholar
• Qiao B, Johnson NW, Gao J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int J Oncol 2010; 37:663-8; PMID:20664935
   PubMed Web of Science ®Google Scholar
• Mighell AJ, Thompson J, Hume WJ, Markham AF, Robinson PA. Human tenascin-C: identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae. Int J Cancer J Int Du Cancer 1997; 72:236-40; PMID:9219826; http://dx.doi.org/10.1002/(SICI)1097-0215(19970717)72:2%3c236::AID-IJC6%3e3.0.CO;2-S
   PubMedGoogle Scholar
• Driemel O, Kosmehl H, Rosenhahn J, Berndt A, Reichert TE, Zardi L, Dahse R. Expression analysis of extracellular matrix components in brush biopsies of oral lesions. Anticancer Res 2007; 27:1565-70; PMID:17595777
   PubMed Web of Science ®Google Scholar
• Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H. High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investigat 2007; 11:93-9; PMID:17111122; http://dx.doi.org/10.1007/s00784-006-0086-8
   PubMed Web of Science ®Google Scholar
• Serini G, Bochaton-Piallat ML, Ropraz P, Geinoz A, Borsi L, Zardi L, Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142:873-81; PMID:9700173; http://dx.doi.org/10.1083/jcb.142.3.873
   PubMed Web of Science ®Google Scholar
• Kohan M, Muro AF, White ES, Berkman N. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J: Off Pub Federat Am Soc Exp Biol 2010; 24:4503-12; PMID:20643910; http://dx.doi.org/10.1096/fj.10-154435
   PubMed Web of Science ®Google Scholar